Filing Flows › Health Care › Iridex (IRIX)
Iridex (IRIX) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 18, 2026 · Iridex (IRIX) Q2 2026 earnings results →
Q2 2026 Revenue down 7% year over year to $12.6M · 10¢ of every $1 of revenue lost · operating margin -8.2%
Iridex made $12.6M in Q2 2026 (-7% Y/Y): Retina $6.5M, Cyclo G Six $3.9M, Product and Service Other $2.2M. Operating margin -8.2%, net loss $1.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 18, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $12.6M in Q2 2026, down 7% year over year and up 7% from the previous quarter. Retina was the largest line at 52% of revenue. Retina lost $1.6M year over year (down 19%), 155% of the total change.
Gross margin was 34.2%, down 0.3 points from Q2 2025. Operating costs exceeded revenue by $1.0M, an operating margin of -8.2%. Operating expenses fell 5% while revenue fell 7%. The quarter ended with a net loss of $1.3M, wider than the previous quarter's $524K loss.
Operating cash flow was $174K. Non-cash charges added back $86K of depreciation and amortization and $212K of share-based compensation. Working capital and other items added $1.1M. Capital expenditures of $50K left free cash flow of $124K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 18, 2026 | $12.6M | -7% | -8.2% | −$1.3M | $174K |
| Q1 2026 | 10-Q | May 19, 2026 | $11.8M | -0.8% | -2.7% | −$524K | −$1.3M |
| Q4 2025 | 10-K | Apr 2, 2026 | $14.7M | +16% | -0.1% | −$184K | $589K |
| Q3 2025 | 10-Q | Nov 12, 2025 | $12.5M | +8% | -11.3% | −$1.6M | −$1.2M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $13.6M | +7% | -6.9% | −$994K | −$397K |
| Q1 2025 | 10-Q | May 13, 2025 | $11.9M | +1% | -1.7% | −$1.7M | −$1.1M |
| Q4 2024 | 10-K | Mar 27, 2025 | $12.7M | +2% | -4.0% | −$834K | −$1.2M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Iridex
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
In its own words, from its 8-K, filed Aug 18, 2026.
Iridex against its Electromedical & Electrotherapeutic Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -7% against the peers' median +14%. Operating margin: -8.2% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| IRIX Iridex | Q2 2026 | $12.6M | -7% | -8.2% |
| MDT Medtronic | Q1 FY27 | $9.8B | +14% | 18.1% |
| ITGR Integer Holdings | Q3 2026 | $450M | -4% | 6.3% |
| LIVN LivaNova | Q3 2026 | $393M | +10% | 7.2% |
| CNMD Conmed | Q3 2026 | $336M | -0.7% | 11.1% |
| TMDX TransMedics Group | Q3 2026 | $203M | +41% | 13.9% |
| AXGN Axogen | Q3 2026 | $75.8M | +26% | 1.3% |
| OM Outset Medical | Q3 2026 | $33.6M | +14% | -36.5% |
| CBLL Ceribell | Q3 2026 | $29.3M | +30% | -70.0% |
Source: Iridex 10-Q on SEC EDGAR · CIK 1006045 · Electromedical & Electrotherapeutic Apparatus
13F: who owns IRIX and who is buying
More on IRIX
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results